MyFinsight
Home
Blog
About
Proceeds from initial
public offering, net of...
$718,240K
Proceeds from issuance of
convertible preferred...
$305,249K
Proceeds from concurrent
private placement of...
$83,333K
Proceeds from issuance of
simple agreement for...
$50,000K
Proceeds from exercise of
stock options
$771K
Net cash provided by
financing activities
$1,146,603K
Canceled cashflow
$10,990K
Increase in cash, cash
equivalents and restricted...
$1,059,349K
Canceled cashflow
$87,254K
Principal payments on debt
$7,500K
Payments of initial
public offering costs
$2,499K
Payments of convertible
preferred stock issuance...
$680K
Principal payments on
finance leases
$311K
Deferred revenue
$41,519K
Change in fair value of
simple agreement for...
$5,556K
Stock-based compensation
expense
$4,938K
Non-cash lease expense
$3,353K
Depreciation and
amortization
$1,199K
Non-cash interest
expense
$133K
Net cash used in
operating activities
-$52,822K
Net cash (used in)
provided by investing...
-$34,432K
Canceled cashflow
$56,698K
Net loss
-$97,779K
Purchases of marketable
securities
$33,447K
Purchases of property and
equipment
$985K
Prepaid expenses and
other assets
$5,364K
Operating lease
liabilities
-$3,510K
Accounts payable,
accrued expenses and...
-$2,659K
Accretion of discounts on
marketable securities
$208K
Back
Back
Cash Flow
Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. (PBLS)
source: myfinsight.com